World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

A 42% cut in melanoma recurrence or death is the kind of number that deserves the front page, and it will get about a third of it.

"This has not been achieved before in the history of cancer drug development." ScienceAlert stories are written, fact-checked, and edited by humans, never generated by AI. Don't miss a story, subscribe here.

Read it at ScienceAlert ↗

← Front page